Paclitaxel Therapeutic Drug Monitoring in Cancer Patients
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Metastatic Breast Carcinoma
- Anatomic Stage IV Breast Cancer AJCC v8
- Recurrent Ovarian Carcinoma
- Stage IVB Vulvar Cancer AJCC v8
- Stage IVA Cervical Cancer AJCC v8
- Invasive Breast Cancer
- Malignant Uterine Neoplasm
- Metastatic Cervical Carcinoma
- Stage IVA Vulvar Cancer AJCC v8
- Solid Tumor, Adult
- Stage IV Lung Cancer AJCC v8
- Metastatic Nonsmall Cell Lung Cancer
- Metastatic Ovarian Carcinoma
- Stage IVB Cervical Cancer AJCC v8
- Stage IV Ovarian Cancer AJCC v8
- Vulvar Cancer
- Vulva Squamous Cell Carcinoma
- Prognostic Stage IV Breast Cancer AJCC v8
- Stage IV Cervical Cancer AJCC v8
- Stage IV Vulvar Cancer AJCC v8
- Recurrent Breast Carcinoma
- Stage IVB Lung Cancer AJCC v8
- Recurrent Vulvar Carcinoma
- Stage IVA Lung Cancer AJCC v8
- Recurrent Cervical Carcinoma
- Recurrent Lung Non-Small Cell Carcinoma
- Stage IVA Ovarian Cancer AJCC v8
- Stage IVB Ovarian Cancer AJCC v8
- Type
- Observational
- Design
- Observational Model: CohortTime Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Primary Objective: • Determine the feasibility of monitoring paclitaxel serum drug levels in patients with a solid tumor (e.g. lung, breast, and gynecologic cancers) for which Paclitaxel is the standard of care. Secondary Objectives: Compare Paclitaxel serum drug levels among patients with differing...
Primary Objective: • Determine the feasibility of monitoring paclitaxel serum drug levels in patients with a solid tumor (e.g. lung, breast, and gynecologic cancers) for which Paclitaxel is the standard of care. Secondary Objectives: Compare Paclitaxel serum drug levels among patients with differing degrees of chemotherapy-induced peripheral neuropathy at the end of Paclitaxel treatment. Compare mitochondrial function within circulating peripheral blood mononuclear cells among patients with differing degrees of chemotherapy-induced peripheral neuropathy at the end of Paclitaxel treatment. Compare the ability of pulsed electromagnetic field to modulate immune cells of individuals experiencing differing degrees of chemotherapy-induced peripheral neuropathy at the end of Paclitaxel treatment.
Tracking Information
- NCT #
- NCT03987555
- Collaborators
- National Cancer Institute (NCI)
- Investigators
- Principal Investigator: Roy Strowd, MD Wake Forest University Health Sciences
Get Well Soon